Clinical Correlations With Lewy Body Pathology in<i>LRRK2</i>-Related Parkinson Disease

Lorraine V. Kalia(University Health Network), Anthony E. Lang(University of Toronto), Lili‐Naz Hazrati(University of Toronto), Shinsuke Fujioka(Mayo Clinic), Zbigniew K. Wszołek(Jacksonville College), Dennis W. Dickson(Mayo Clinic in Florida), Owen A. Ross(WinnMed), Vivianna M. Van Deerlin(Philadelphia University), John Q. Trojanowski(University of Pennsylvania), Howard I. Hurtig(University of Pennsylvania), Roy N. Alcalay(Columbia University), Karen Marder(Columbia University), Lorraine N. Clark(Columbia University), Carles Gaig(Universitat de Barcelona), Eduardo Tolosa(Centro de Investigación Biomédica en Red), Javier Ruiz‐Martínez(Biogipuzkoa Health Research Institute), J.F. Martí-Massó(Biogipuzkoa Health Research Institute), Isidró Ferrer(Bellvitge University Hospital), Adolfo López de Munaín(Biogipuzkoa Health Research Institute), Samuel M. Goldman(San Francisco VA Medical Center), Birgitt Schüle(Parkinson's Institute and Clinical Center), J. William Langston(Parkinson's Institute and Clinical Center), Jan Aasly(St Olav's University Hospital), Maria Teresa Giordana(University of Turin), Vincenzo Bonifati(Erasmus University Rotterdam), Andreas Puschmann(Lund University), Margherita Canesi(Istituti Clinici di Perfezionamento), Gianni Pezzoli(Istituti Clinici di Perfezionamento), A. Maues de Paula(Hôpital de la Timone), Kazuko Hasegawa(National Sagamihara Hospital), Charles Duyckaerts(Institut du Cerveau), Alexis Brice(Sorbonne Université), A. Jon Stoessl(University of British Columbia), Connie Marras(University of Toronto)
JAMA Neurology
November 17, 2014
Cited by 403Open Access
Full Text

Abstract

IMPORTANCE: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 mutation carriers are generally indistinguishable from those of patients with sporadic PD. However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a neuropathological hallmark of PD. We investigated whether the presence or absence of LBs correlates with different clinical features in LRRK2-related PD. OBSERVATIONS: We describe genetic, clinical, and neuropathological findings of 37 cases of LRRK2-related PD including 33 published and 4 unpublished cases through October 2013. Among the different mutations, the LRRK2 p.G2019S mutation was most frequently associated with LB pathology. Nonmotor features of cognitive impairment/dementia, anxiety, and orthostatic hypotension were correlated with the presence of LBs. In contrast, a primarily motor phenotype was associated with a lack of LBs. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first report of clinicopathological correlations in a series of LRRK2-related PD cases. Findings from this selected group of patients with PD demonstrated that parkinsonian motor features can occur in the absence of LBs. However, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonian symptom complex including cognitive impairment.


Related Papers

No related papers found

Powered by citation graph analysis